Toxoplasmosis Treatment Market Research, 2031
The global toxoplasmosis treatment market size was valued at $683.1 million in 2021, and is projected to reach $1,093.88 million by 2031, growing at a CAGR of 4.8% from 2022 to 2031. Toxoplasmosis is an infection caused by common parasite, which is found in cat feces and in contaminated food. This parasite is known as Toxoplasma gondii. The symptoms of toxoplasmosis disease include body aches and pain, headache, fatigue, fever, and swollen lymph nodes. In addition, people with weakened immune system who receive chemotherapy, a previous toxoplasma infection may reactivate and cause the symptoms such as headache, confusion, poor coordination, and seizures.
Toxoplasmosis can be diagnosed through computed tomography scan, magnetic resonance imaging, contrast agents, biopsy, and polymerase chain reaction, while pregnant women are treated with sulphadiazine and spiramycin drugs. The toxoplasmosis disease is classified as acquired toxoplasmosis and congenital toxoplasmosis.
According to Cancer Statistics by the National Cancer Institute, in 2020, an estimated 1,806,590 new cases of cancer were diagnosed in the U.S. and 606,520 people died from the disease, which highlights the higher utilization of the chemotherapy treatment. As the rise in chemotherapy procedures can lead to rise in number of toxoplasmosis infection, thus, this highlights the need for the toxoplasmosis treatment for the patient, leading to the expansion of the market.
Increase in awareness about foodborne illness drives the growth of market. In addition, surge in government support for healthcare infrastructure further boosts the growth of the market. Moreover, rise in parasitic infection and surge in use of Daraprim drug for the treatment of toxoplasmosis infections further contribute toward the growth during toxoplasmosis treatment market forecast.
However, side effects toxoplasmosis drugs such as toxic epidermal necrolysis, erythema multiforme, and hyperphenylalaninemina may hinders the market growth. Moreover, rise in product launches for the treatment of toxoplasmosis disease is projected to provide the beneficial opportunities for toxoplasmosis treatment market growth. For instance, in March 2020, Oakrum Pharma, a biopharmaceutical company, announced the launch of Pyrimethamine 25mg tablets in the U.S.
Impact of COVID-19
The outbreak of COVID-19 has disrupted workflows in the health care sector across the world. The disease has forced a number of industries to shut their doors temporarily, including several sub-domains of health care. However, there has been a negative effect on toxoplasmosis treatment industry that include decrease in demand for toxoplasmosis during pandemic. The significant reduction in clinical trials for toxoplasmosis treatment, owing to strict government guidelines against COVID-19 restrains the growth of market. Decline in hospitals visit, closing of borders, and confinement of the population impacted the supply chains of these life-saving medical products in the toxoplasmosis treatment industry.
TOXOPLASMOSIS TREATMENT MARKET SEGMENTATION
The toxoplasmosis treatment market size is segmented into type, route of administration, distribution channel, and region. By type, the market is categorized into acquired toxoplasmosis and congenital toxoplasmosis. By route of administration, it is bifurcated into oral and parenteral. By distribution channel, it is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
Segment Review
Depending on type, the market is segmented into acquired toxoplasmosis and congenital toxoplasmosis. The acquired toxoplasmosis segment dominated the global market in 2021. This was attributed to rise in prevalence of parasitic infection that causes acquired toxoplasmosis. However, the congenital toxoplasmosis segment is projected to register highest CAGR during the forecast period. This is attributed to eating undercooked meat that contains cysts or by consuming oocysts produced from cat feces or contaminated food or water, which causes the congenital toxoplasmosis due to Toxoplasma gondii parasite.
On the basis of route of administration, the market is bifurcated into oral and parenteral. The oral segment accounted for the largest toxoplasmosis treatment market share in 2021 and is expected remain dominant during forecast period. This is attributed to high adoption of oral drugs due to noninvasive, high patient compliance, convenient to handle, and does not require any specific sterile conditions.
On the basis of distribution channel, the market is segmented into hospital pharmacies, drug stores & retail pharmacies, and online providers. The hospital pharmacies accounted for the largest revenue in 2021. This was attributed to availability of toxoplasmosis drugs and rise in number of hospital pharmacies to treat the toxoplasmosis disease.
However, the online providers segment is projected to register highest CAGR during the forecast period. This is attributed to increase in number of smartphone users and higher internet penetration to buy the medicines. For instance, according to report of Global System for Mobile Communications (GSMC), a global organization unifying the mobile ecosystem, in 2021, there were estimated 5.3 billion unique mobile phone users in which 4.2 billion users have active mobile phone internet connection. Furthermore, innovative marketing strategies, introduction of new business models, and upsurge in the pharmacies & wellness stores have been anticipated to propel growth of the segment.
Region wise, North America acquired a major toxoplasmosis treatment market share, owing to the presence of key players, rise in government initiatives, well-developed healthcare infrastructure, and increase in prevalence of cancer disease that causes toxoplasmosis.
However, Asia-Pacific is expected to witness the highest growth rate for the toxoplasmosis treatment market throughout the forecast period. The factor that drives the growth of the toxoplasmosis treatment market in this region is the increase in demand for toxoplasmosis treatment. In addition, rise in government initiatives to promote healthy lifestyle are driving the market growth. Moreover, rise in number of hospitals pharmacies for toxoplasmosis treatment in this region further boost the market growth.
The key market players profiled in the report include Alvogen, Dr. Reddy's Laboratories Ltd., Kaiser Permanente, Mangalam Drugs and Organics Ltd., Manus Aktteva Biopharma LLP, Oakrum Pharma, Omicron pharmaceuticals, Teva Pharmaceutical Industries Ltd., Vyera Pharmaceuticals LLC, and Zorish Healthcare Private Limited.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the toxoplasmosis treatment market analysis from 2021 to 2031 to identify the prevailing toxoplasmosis treatment market opportunity.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the toxoplasmosis treatment market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global toxoplasmosis treatment market trends, key players, market segments, application areas, and market growth strategies.
Toxoplasmosis Treatment Market Report Highlights
| Aspects | Details |
 Market Size By 2031 | USD 1.1 billion |
 Growth Rate | CAGR of 4.8% |
 Forecast period | 2021 - 2031 |
 Report Pages | 210 |
 By Type |
|
 By Route of Administration |
|
 By Distribution Channel |
|
 By Region |
|
 Key Market Players | Zorish Healthcare Private Limited, omicron pharmaceuticals, Manus Aktteva Biopharma LLP, Alvogen, Oakrum Pharma, Vyera Pharmaceuticals LLC, Dr Reddy's Laboratories Ltd., Kaiser Permanente, Mangalam Drugs and Organics Ltd., Teva Pharmaceutical Industries Limited |
Analyst Review
The global toxoplasmosis treatment market is expected to exhibit high growth potential attributable to factors such as rise in R&D activities in pharmaceutical industry for manufacturing of the toxoplasmosis drugs; increase in prevalence of cancer, and surge in number advancements in the diagnosis & treatment for toxoplasmosis disease.
Toxoplasmosis treatment is used to treat the patients who suffer from toxoplasmosis diseases caused by Toxoplasma gondii.
Furthermore, North America is expected to witness highest growth, in terms of revenue, owing to presence of key players, rise in government initiatives, well-developed healthcare infrastructure, and surge in prevalence of health issues. Asia-Pacific is expected to register highest growth during the forecast period, owing to rise in healthcare infrastructure.
The total market value of toxoplasmosis treatment market is $683.11 million in 2021.
The market value of toxoplasmosis treatment market in 2031 is $1,093.88 million
Top companies such as Dr. Reddy's Laboratories Ltd., Oakrum Pharma, Omicron pharmaceuticals, Mangalam Drugs and Organics Ltd. and Teva Pharmaceutical Industries Ltd. held a high market position in 2021. These key players held a high market postion owing to the strong geographical foothold in different regions.
The forecast period for toxoplasmosis treatment market is 2022 to 2031
The base year is 2021 in toxoplasmosis treatment market.
The major factor that fuels the growth of the toxoplasmosis treatment market are increase in prevalence of foodborne illness and t increase in awareness regarding toxoplasmosis treatment.
Acquired toxoplasmosis segment is the most influencing segment in toxoplasmosis treatment market which is attributed to rise in prevalence of acquired toxoplasmosis caused due to eating contaminated food.
Toxoplasmosis treatment includes inhibitors of dihydrofolate reductase (DHFR) (pyrimethamine and trimethoprim), and dihydropteroate synthetase (sulfonamides, such as sulfadiazine, sulfamethoxazole, and sulfadoxine), which block the folic acid synthesis. This treatment is used in patients who are suffering from parasitic infection (toxoplasmosis disease).
Loading Table Of Content...
